A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Insulin Human (AFREZZA)

Insulin class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval1994-03-31
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$5.05/unit
7 NDCs benchmarked, lowest of all strengths.
Average NADAC
$29.76
Across all dosage forms in distribution.
Highest NADAC
$91.66
Wide spread — brand-strength NDCs still in market.
Plans with PA
150 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Insulin Human used for?

Insulin Human is a Insulin medication tracked in Medicare Part D.

Is there a generic for Insulin Human?

No. Insulin Human is brand-only with no generic equivalents currently in market.

How much does my plan pay for Insulin Human?

Across 329 Part D plans, Insulin Human averages $29.76/unit (NADAC). Lowest available: $5.05/unit. Highest in distribution: $91.66/unit.

Is Insulin Human on the FDA shortage list?

No. Insulin Human is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (7 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.